7 GOLDA MEIR ST., NESS ZIONA, L3
To appoint Kesselman & Kesselman as independent auditors and approve the re-election of directors
To Host KOL Investor Day for SGT-610 on October 14, 2026
Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome
Announces Financial Results for the Quarter Ended June 30, 2026
Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Announces Pricing of Oversubscribed Underwritten Offering
Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease
Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload